ESPR FY2024 SEC EDGAR DEF 14A

Esperion Therapeutics, Inc. CEO pay ratio

The CEO earned $3.2M in FY2024 against median worker pay of $198,453 · Chemicals & Pharmaceuticals.

State
DE
Filing date
2025-04-17
Industry
Chemicals & Pharmaceuticals
Fiscal year
FY2024

Data updated August 2026

Subscribe to Esperion Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
16:1
Below Average (Scale: 0–1000:1)
CEO pay
$3.2M
Median worker
$198,453

Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.

Answer first

Esperion Therapeutics, Inc. reported a 16:1 CEO-to-worker pay ratio in FY2024 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.

Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Pay ratio
16:1
FY2024 disclosed
CEO total
$3.2M
Summary Compensation Table total
Median worker
$198,453
Dodd-Frank median employee

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2024

A component-level pay breakdown is not reported in Esperion Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
16:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$3.2M
Companies in Industry
168
vs. Industry Median
Below

Esperion Therapeutics, Inc.: near-parity Item 402(u) ratio

Esperion Therapeutics, Inc. stamps FLOOR · ELITE-MED at 16:1 against $198,453 median worker pay in FY2024. the CEO earned 16× the median employee ($198,453) in FY2024.

At $198,453 median worker pay, the FLOOR stamp is near pay-parity territory under MID$ CEO total.

CEO Total Pay

$3.2M

FY2024 Summary Compensation, below median

Pay Ratio

16:1

Below typical

What FY2024 shows for Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. stamps FLOOR · ELITE-MED at 16:1 against $198,453 median worker pay in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Esperion Therapeutics, Inc.'s $3.2M CEO total is at or below the $7.9M industry median CEO pay.

Esperion Therapeutics, Inc. stamps FLOOR · MID$ · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2024

Total Compensation
$3.2M
Median Employee Pay
$198,453
Pay Ratio
16:1
Filing Date
2025-04-17

Company Info

Ticker
ESPR
CIK
1434868
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
SEC EDGAR DEF 14A for CIK 1434868, FY2024. Informational only, not investment advice. Verify on EDGAR.

Read with Esperion Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MID$ · ELITE-MED.

Data sourced from SEC EDGAR DEF 14A for Esperion Therapeutics, Inc. (CIK 1434868), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.